Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)
Objectives The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI in the setting of acute coronary syndrome.
Background Greater platelet inhibition has been associated with improved angiographic outcomes before and after percutaneous coronary intervention (PCI). Therefore, it was hypothesized that treatment with ticagrelor, which achieves more rapid, higher, and more consistent platelet inhibition, would be associated with improved angiographic outcomes when compared with those of clopidogrel treatment.
Methods The angiographic cohort consists of 2,616 patients drawn from the 18,624-patient PLATO trial. Clopidogrel naïve or pre-treated patients were randomized to 180 mg of ticagrelor or 300 mg of clopidogrel (75 mg for clopidogrel pre-treated patients). PCI patients were administered, as per treatment group: 1) an additional 90 mg of ticagrelor if >24 h following the initial loading dose; or 2) an optional further 300 mg of clopidogrel or placebo (total 600 mg) prior to PCI. The substudy primary endpoint was the incidence of post-PCI TIMI (Thrombolysis In Myocardial Infarction) myocardial perfusion grade 3 (TMPG 3) among patients who received a study drug prior to PCI.
Results In total, 21.3% of patients were pretreated with clopidogrel prior to randomization. There was a short time interval between randomization and PCI (median: 0.68 [interquartile range (IQR): 0.30 to 2.21] h) among all patients. Post-PCI TMPG 3 was similar between the ticagrelor and clopidogrel groups (47.1% vs. 46.9%; p ¼ 0.96). Likewise, the following pre-PCI outcomes were similar in the ticagrelor and clopidogrel groups, respectively: TMPG 3 (30.5% vs. 31.2%), TIMI flow grade 3 (37.1% vs. 39.3%), corrected TIMI frame count (median: 100 vs. 71 frames), TIMI thrombus grade 0 (24.1% vs. 27.6%), minimum lumen diameter (median: 0. In the PLATO (Platelet Inhibition and Patient Outcomes) trial (1), long-term treatment with ticagrelor, compared with clopidogrel, results in a significant reduction in the composite endpoint of death from vascular causes, myocardial infarction (MI), or stroke among patients presenting with acute coronary syndromes (ACS). Ticagrelor inhibits platelet activation and aggregation by selectively and reversibly blocking platelet P2Y 12 receptors (2) . The likely mechanism of clinical benefit is thought to be more potent and more predictable P2Y 12 inhibition with ticagrelor compared with clopidogrel (3-5). Greater platelet inhibition with glycoprotein IIb/IIIa inhibitors has been associated with improved angiographic outcomes before and after percutaneous coronary intervention (PCI). In particular, greater platelet inhibition has been associated with improved myocardial perfusion before and after PCI, and improvements in myocardial perfusion have in turn been associated with improved clinical outcomes (6) (7) (8) (9) . Therefore, it could be hypothesized that the greater platelet inhibition associated with ticagrelor may in turn lead to improved angiographic outcomes that may be associated with the superior clinical outcomes associated with ticagrelor administration. Ticagrelor is also known to inhibit cell uptake of adenosine, and it could also be hypothesized that, by inhibiting this process, ticagrelor might increase adenosine's concentration in the myocardium and thereby further enhance the positive and beneficial effects of adenosine in the microvasculature, such as hyperemia and vasodilation, and minimize reperfusion injury in the myocardium.
The goal of the PLATO angiographic substudy was to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI.
Methods
Main study design. The PLATO trial was a multicenter, randomized, double-blind study (10) . The primary results and the details of the design are published elsewhere (10) . The angiographic substudy was designed in collaboration with the academic chairs and members of the steering committee. The angiographic data were collected by the PERFUSE (Pharmacologic/Percutaneous Endoluminal Revascularization For Unstable Syndromes and its Evaluation) study group, an academic research organization. The sponsor coordinated the data management. The statistical analysis of the angiographic substudy was performed by Duke Clinical Research Institute in collaboration with the investigators. National and local regulatory and ethics committees approved the PLATO trial. All subjects provided written informed consent. Study patients. Inclusion criteria for enrollment included hospitalization for an ACS, with or without ST-segment elevation, with an onset of symptoms during the previous 24 h. For patients who had an ACS without ST-segment elevation (non-ST-segment elevation [NTSE]), or NTSE-ACS, at least 2 of the following 3 criteria had to be met: 1) STsegment changes on electrocardiography, indicating ischemia; 2) a positive test of a biomarker, indicating myocardial necrosis; or 3) 1 of several risk factors (age 60 years; previous MI or coronary artery bypass graft; coronary artery disease with stenosis of 50% in at least 2 vessels; previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of <60 ml/min per 1.73 m 2 of body surface area). For patients who had an ACS with ST-segment elevation, the following 2 inclusion criteria had to be met: 1) either persistent ST-segment elevation of at least 0.1 mV in at least 2 contiguous leads or a new left bundle branch block; and 2) the intention to perform primary PCI. Key major exclusion criteria were any contraindication to the use of clopidogrel, fibrinolytic therapy within 24 h before randomization, a need for oral anticoagulation therapy, an increased risk of bradycardia, and concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer. All sites were invited to participate in the angiographic substudy. Study treatment. Patients were randomly assigned to receive either ticagrelor or clopidogrel, administered in a double-blind, double-dummy fashion. Patients were clopidogrel-naïve or pre-treated. Ticagrelor was administered as a loading dose of 180 mg followed by a maintenance dose of 90 mg twice daily. Patients in the clopidogrel group who had not received an open-label loading dose, or who had not been taking clopidogrel for at least 5 days before randomization, received a 300-mg loading dose of clopidogrel followed by a dose of 75 mg daily. Other patients in the clopidogrel group continued to receive a maintenance dose of 75 mg daily. Patients undergoing PCI following randomization received, in a blinded fashion, an additional dose of their study drug at the time of PCI: 300 mg of clopidogrel, at the investigator's discretion; or 90 mg of ticagrelor for patients who were undergoing PCI more than 24 h following randomization. All patients received acetylsalicylic acid (aspirin) at a maintenance dose of 75 to 100 mg daily unless they could not tolerate the drug. For those who had not previously been treated with aspirin, up to 325 mg was the preferred loading dose; 325 mg was also permitted as the daily dose for 6 months following stent implantation. Angiographic endpoints. Angiography was performed according to local practice patterns. The TIMI (Thrombolysis In Myocardial Infarction) myocardial perfusion grade (TMPG) (11, 12) , corrected TIMI frame count (CTFC) (13) , TIMI flow grade (14) , angiographic perfusion score (15) , TIMI thrombus grade (16) , minimum lumen diameter, and percentage of diameter stenosis were assessed at the PERFUSE angiographic core laboratory and were blinded to treatment assignment.
The primary efficacy endpoint was the incidence of normal TMPG (TMPG 3) following PCI among all patients who were treated with the study drug prior to PCI. The following secondary endpoints were also assessed: the CTFC following PCI in all patients who were treated with the study drug prior to PCI. Among patients who were treated with an active drug prior to cardiac catheterization, the following pre-PCI endpoints were secondary endpoints: pre-PCI TMPG, CTFC, TIMI thrombus grade, TIMI flow grade, minimum lumen diameter, and percentage of diameter stenosis. Statistical analysis. Based on a post-PCI TMPG 3 rate of 52% in the clopidogrel arm in NSTE-ACS patients and 48% in the clopidogrel arm in ST-segment elevation myocardial infarction (STEMI) patients, 1,628 patients (814 per arm) would be required to detect a 20% difference with ticagrelor given 80% power (previous experience, unpublished data). To allow for nonevaluable angiograms and dropouts, 1,800 patients were planned to be enrolled in this substudy. It was planned to recruit an equal number of patients with STEMI (n ¼ 900) and NSTE-ACS (n ¼ 900) into the substudy. Baseline characteristics were compared between the 2 treatment groups using Fisher exact test for categorical variables or the Wilcoxon rank-sum test for continuous variables. The interaction between randomized treatment and presenting syndrome for the primary angiographic endpoint was tested using a logistic regression model. The primary endpoint was also analyzed stratifying by presenting syndrome: either NSTE-ACS or STEMI. A p value of <0.05 was considered statistically significant. All analyses In patients with clopidogrel pre-randomization <600 mg/day n ¼ 1,012 n ¼ 510 n ¼ 502 Tables 1 and 2 . were carried out using SAS software (version 9.2, SAS Institute Inc., Cary, North Carolina) statistical software.
Results
In the main PLATO trial, there were 18,624 patients with ACS, recruited from 862 centers in 43 countries, who were randomized to either ticagrelor or clopidogrel. The angiographic substudy consisted of 2,616 patients ( Fig. 1) , of whom 2,068 received the study drug (ticagrelor: n ¼ 1,053, and clopidogrel: n ¼ 1,015) prior to PCI and are included in the present analysis. Of these, 1,657 PCI patients had angiographic images that were suitable for the analysis of the primary endpoint (TMPG). There were 27 countries and 161 sites that contributed to the PLATO angiographic substudy.
Baseline characteristics. The baseline characteristics of the angiographic substudy patients are displayed in Table 1 . The mean age was 61 AE 10.9 years among all patients included in the angiographic substudy. In total, 95.3% of patients were identified by the investigator as intended for invasive management at the time of randomization, and the remaining patients were initially intended for medical management. In accordance with the planning, approximately one-half of the angiography substudy cohort consisted of patients with a final diagnosis of STEMI (55.8%) and one-half with a final diagnosis of NSTE-ACS: that is, non-STEMI (34.6%) and unstable angina (8.7%). There were no significant differences in the baseline variables between the ticagrelor and clopidogrel groups. In total, 21.3% of patients received clopidogrel prior to randomization with no difference between the 2 study groups (22.4% vs. 20.1% in the ticagrelor and clopidogrel groups, respectively; p ¼ 0.2164). The timing of procedures following the administration of the study drug is displayed in Table 2 (Table 3) . Among the patients with available primary endpoint, 388 (23%) patients (311 NSTE-ACS and 77 STEMI) had the angiography 1 h or later following the administration of the first dose of the study drug. Of the 311 NSTE-ACS patients, 154 were randomized to ticagrelor and 157 to clopidogrel. TMPG 3 was observed in 79 of 154 patients (51.3%) in ticagrelor versus 84 of 157 patients (53.5%) in clopidogrel groups (p ¼ 0.73).
Among the patients with available primary endpoint, 305 (18%) patients (259 NSTE-ACS and 46 STEMI) had the angiography 2 h or later following the administration of the first dose of the study drug. Of the 259 NSTE-ACS patients, 133 were randomized to ticagrelor and 126 to clopidogrel. TMPG 3 was observed in 65 of 133 (48.9%) Values are n (%).
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J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3
Kunadian et al. Further, there was no difference in the post-PCI TMPG between ticagrelor and clopidogrel groups among patients who were administered clopidogrel pre-randomization, which is defined as open-label clopidogrel received on the day of randomization or the day before randomization, and those who were administered open-label clopidogrel prerandomization plus investigational product clopidogrel/ placebo dose (within 24 h of the first dose of investigational product) (Table 3 ). There was no difference in the post-PCI TMPG between the 2 treatment groups among patients who received different doses of aspirin and the results are displayed in Table 4 . There was also no difference in the post-PCI TMPG between the 2 treatment groups among patients who did and did not receive glycoprotein IIb/IIIa inhibitors on the day of randomization and the results are displayed in Table 5 . Angiographic secondary endpoints post-PCI. Complete procedural success (<50% stenosis and TIMI flow grade 3) occurred in 886 (88.1%) patients in the ticagrelor group and 852 (88.4%) in the clopidogrel group ( (Table 9) .
Discussion
Enhanced platelet inhibition with intravenous glycoprotein IIb/IIIa inhibitors has been associated with improved angiographic outcomes before and after PCI (6-8). Therefore, it was hypothesized that ticagrelor, compared with clopidogrel, might improve angiographic outcomes because of its more potent and predictable platelet inhibition. However, among patients randomized to either ticagrelor or clopidogrel, the primary hypothesis in the PLATO angiographic substudy failed with no significant difference in myocardial perfusion, epicardial flow, PCI complications, or other angiographic outcomes either before or after PCI. The inclusion of patients pretreated with clopidogrel may have minimized the ability to discern differences in angiographic outcomes immediately following PCI that would be attributable to platelet inhibition. Interestingly, more patients in the ticagrelor group had diffuse disease. However, this should be interpreted with caution given the small number of patients that had diffuse disease overall. Adenosine induces vasodilation by interacting with A 2A adenosine receptors in the smooth muscle cells. In clinical studies, intracoronary adenosine has been demonstrated to improve CTFC (17, 18) . Despite the inhibition of cellular adenosine reuptake and, thereby, extended half-life and increased presence of extracellular adenosine by ticagrelor (19) , there were no significant differences in improvement in epicardial flow or myocardial perfusion among patients treated with ticagrelor versus clopidogrel. Ticagrelor has previously been shown to augment adenosine-induced increase in coronary blood flow in volunteers without ischemia (20) . In the absence of infused adenosine, such an effect could not be determined in PLATO patients. Absence of an effect could be due to lack of sufficient local endogenous adenosine to influence the angiographic measurements. Intracoronary nitrate administration has been demonstrated to influence coronary flow (21, 22) . In the present PLATO angiographic substudy, details of intracoronary nitrate administration and the potential effects of intracoronary nitrate overriding any influence of adenosine are not known. Moreover, in the present study, aspirin dosages and use of glycoprotein IIb/IIIa inhibitors did not have any impact on the primary angiographic outcome.
Prior data in healthy volunteers demonstrated that absorption of ticagrelor was rapid (median time to peak plasma concentration [t max ] 1.3 to 2 h), as was the formation of its main (active) metabolite, AR-C124910XX, t max 1.5 to 3 h (23). In the present PLATO angiography substudy, the duration of exposure to ticagrelor was short, given that PCI was performed 0.7 h (median) following 180 mg of ticagrelor and shortly after presentation with ACS symptoms. This allowed little time to affect myocardial perfusion as measured using TMPG.
Ticagrelor achieved more rapid and greater platelet inhibition than high-loading-dose clopidogrel did in the ONSET-OFFSET study (24) . In another analysis from the ONSET-OFFSET study, maximum (peak) plasma concentration (C max ), time to C max (t max ), and area under the plasma concentration-time curve from time 0 to 8 h (AUC 8 ) for ticagrelor were 733 ng/ml, 2.0 h, and 4,130 ng $ h/ml, respectively (25) . In the RESPOND (Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies) study (26) , ticagrelor therapy overcame the nonresponsiveness to clopidogrel, and its antiplatelet effect was the same in responders and nonresponders among patients with stable coronary artery disease. In another analysis from the RESPOND study, ticagrelor mean C max and area under the curve following 2-week dosing were comparable between clopidogrel responders (724 ng/ml and 3,983 ng $ h/ml, respectively) and nonresponders (764 ng/ml and 3,986 ng $ h/ml, respectively). Pharmacokinetics of ticagrelor were unaffected by prior clopidogrel dosing (25) . In the PLATO angiographic substudy consisting of unstable patients (unstable angina, NSTE-ACS, STEMI), overall, 21.3% of patients had received clopidogrel 600 mg before randomization and demonstrated no difference in the angiographic outcomes between the 2 groups.
Although these data are in healthy volunteers and stable patients, the pharmacokinetics might be different in the setting of ACS. In a recent study by Alexopoulos et al. (27) , among patients with STEMI undergoing primary PCI treated with ticagrelor, the pharmacodynamic (PD) effects were slower than those reported from other studies (i.e., ONSET-OFFSET and RESPOND) in stable patients. The PLATO angiographic substudy consisted of patients with STEMI, unstable angina, and NSTE-ACS. Therefore, slower PD effects of ticagrelor and short duration of exposure of the drug might explain the lack of difference in the angiographic outcomes compared with those of clopidogrel.
Given the short time interval of ticagrelor exposure in the PLATO angiographic substudy, the ATLANTIC (A 30 Day Study to Evaluate Efficacy and Safety of Pre-Hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention) study, which is currently underway, will assess the efficacy and safety of pre-hospital versus in-hospital administration of ticagrelor coadministered with aspirin, on restoring blood flow in occluded coronary arteries and improving myocardial perfusion among STEMI patients undergoing primary PCI.
The ERASE MI (Early Rapid Reversal of Platelet Thrombosis With Intravenous Elinogrel Before PCI To Optimize Reperfusion in Acute Myocardial Infarction) pilot trial (28) , was a phase IIA, randomized, double-blind, placebo-controlled, dose-escalation study designed to evaluate the safety of escalating doses (10, 20, 40 , and 60 mg) of elinogrel, a P2Y 12 inhibitor administered as a single intravenous bolus before the start of the diagnostic angiogram preceding primary PCI. In ERASE MI, using an intravenous P2Y 12 inhibitor prior to primary PCI compared with placebo, there were no differences in CTFC (28). The PD differences between glycoprotein IIb/IIIa inhibitors and P2Y 12 inhibitors might explain the lack of significant impact of ticagrelor on TMPG (29) . An oral P2Y 12 agent such as ticagrelor has a slower and weaker PD effect and blocks a single platelet receptor when compared with a glycoprotein IIb/IIIa inhibitor that profoundly blocks the platelet response to all agonists. This is important because the hypothesis for the PLATO angiographic substudy was based on the observations made from studies using glycoprotein IIb/IIIa inhibitors. It has been suggested that small molecule glycoprotein IIb/IIIa can replace fibrinogen in platelet aggregates and can cause disaggregation, particularly in microvasculature (29) . In the present study, the primary endpoint of TMPG 3 was not achieved in the presence of P2Y 12 receptor inhibition with ticagrelor versus clopidogrel among those that did and did not receive a glycoprotein IIb/IIIa inhibitor. Study limitations. The angiographic substudy is limited by its small sample size. Not all angiographic parameters were evaluable in all angiograms. The timing of PCI procedures following oral study drug administration was short and varied among patients. An imaging technique performed several days after rather than immediately following PCI (e.g., cardiac magnetic resonance imaging) might have detected the target and more subtle changes, such as hyperenhancement, that may have ensued later following the procedure rather than at the completion of the procedure.
Conclusions
Neither coronary flow nor myocardial perfusion evaluated on coronary angiograms performed before or after PCI procedures within a few hours after start of oral antiplatelet treatment in the setting of AC, demonstrated a difference with ticagrelor versus clopidogrel.
